Direct oral anticoagulant and AKI: apixaban-induced acute interstitial nephritis.
Publication/Presentation Date
6-29-2019
Abstract
Direct oral anticoagulants (DOACs)-dabigatran, rivaroxaban, apixaban and edoxaban-are changing the landscape of clinical practice for patients requiring short and long-term anticoagulation. We report a patient with no history of kidney disease developing acute interstitial nephritis (AIN) after starting a DOAC, apixaban. To date, this is the first biopsy proven case of apixaban-induced AIN.
Volume
12
Issue
6
ISSN
1757-790X
Published In/Presented At
DiMaria, C. Hanna, W. Murone, J. Reichart, J. (2019). Direct oral anticoagulant and AKI: apixaban-induced acute interstitial nephritis. BMJ Case Reports CP 2019;12:e230371.
Disciplines
Internal Medicine
PubMedID
31256051
Department(s)
Department of Medicine, Department of Medicine Faculty
Document Type
Article
COinS
Comments
Republished: Direct oral anticoagulant and AKI: apixaban-induced acute interstitial nephritis.
PMID: 31624064